ArticlemSystems2021
Recurrent Vulvovaginal Candidiasis: a Dynamic Interkingdom Biofilm Disease of
Article in mSystems, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Contribution ofFrontiers in cellular and infection microbiology · 2021Pooled it
- Honghe Fujie lotion ameliorates pregnancy-associated vulvovaginal candidiasis in mice by inhibiting the activation of NLRP3 inflammasome.Experimental animals · 2026Article
- Anti-Candida albicans and anti-virulence activities of vaginal Lactobacillus strains from asymptomatic women: phenotypic characterization and prediction of antimicrobial peptide gene clusters.Folia microbiologica · 2026Article
- Effect of postbiotics on biofilm formation and gene expression in Candida spp. isolates from patients with recurrent vulvovaginal candidiasis.Medical mycology · 2026Article
- Characterization of the vaginal microbiome and its metabolic potential in Colombian patients with recurrent vulvovaginal candidiasis.Medical mycology · 2026Article
- Ferroptosis in Recurrent Vulvovaginal Candidiasis Through Integrated Bioinformatics and Experimental Validation.Antioxidants (Basel, Switzerland) · 2026Article
- State-of-the-Art Review: Managing Vulvovaginal Candidiasis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Review
- Non-Frontiers in microbiology · 2026Review
- Inhibitory effect ofFrontiers in cellular and infection microbiology · 2026Article
- Evaluation ofFrontiers in microbiology · 2026Article
- VaginalFrontiers in microbiology · 2026Article
- Vaginal Microbiota Dysbiosis and Infections: A Comprehensive Review of Microbial and Therapeutic Perspectives.International journal of women's health · 2026Review
- Nationwide epidemiology of candidiasis in Panama, 2010-2020.Scientific reports · 2025Article
- Limosilactobacillus fermentum KBL674 Alleviates Vaginal Candidiasis.Probiotics and antimicrobial proteins · 2025Article
- Profiling of vaginal microbial communities in Chilean women via self-sampling and nanopore sequencing.Scientific reports · 2025Article
- Perspectives on Vaginal Ecology and Management of Recurrent Vulvovaginal Candidiasis: A Narrative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Virulence factors, biofilm formation and antifungal resistance in Candida albicans from recurrent vulvovaginal candidiasis patients: a comparative study.Scientific reports · 2025Article
- Impact of Biofilm Formation by VaginalJournal of fungi (Basel, Switzerland) · 2025Article
- Through thick and thin: The vaginal microbiome as both occupant and healer.PLoS pathogens · 2025Article
- Vaginal mycobiome characteristics and therapeutic strategies in vulvovaginal candidiasis (VVC): differentiating pathogenic species and microecological features for stratified treatment.Clinical microbiology reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
Abstract
Despite the strikingly high worldwide prevalence of vulvovaginal candidiasis (VVC), treatment options for recurrent VVC (RVVC) remain limited, with many women experiencing failed clinical treatment with frontline azoles. Further, the cause of onset and recurrence of disease is largely unknown, with few studies identifying potential mechanisms of treatment failure. This study aimed to assess a panel of clinical samples from healthy women and those with RVVC to investigate the influence of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.